Leflunomide Cf (Leflunomide)

Leflunomide blocks the enzyme dihydroorotate dehydrogenase, which is essential for de novo pyrimidine synthesis. This limits the production of nucleotides needed for rapidly dividing lymphocytes, especially activated T‑cells, thereby dampening the autoimmune response that drives arthritis.

The dosing regimen for Leflunomide Cf is individualized by the prescribing clinician based on the patient’s condition, disease severity, and laboratory monitoring. Physicians determine the appropriate loading and maintenance doses and adjust them according to therapeutic response and safety parameters.

Leflunomide is classified as Pregnancy Category X, meaning it is contraindicated during pregnancy because of proven teratogenicity. Women of child‑bearing potential must use effective contraception, and the drug should not be used while breastfeeding, as it may pass into milk and affect the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Leflunomide Cf. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The primary alternative to Leflunomide in rheumatoid and psoriatic arthritis is methotrexate, a folate antagonist. While both are disease‑modifying agents, Leflunomide is taken orally and may be preferred when methotrexate is poorly tolerated or contraindicated. Leflunomide has a distinct safety profile, notably a higher risk of liver enzyme elevation, whereas methotrexate carries risks of pulmonary toxicity and folate deficiency.

Leflunomide Cf should be stored at room temperature, below 25 °C, in its original container. Keep the product away from moisture, direct sunlight, and excessive heat. Ensure the packaging remains sealed until use to maintain stability and potency.

Leflunomide is administered orally, usually as a tablet taken with or without food. Patients should swallow the tablet whole with a glass of water and follow the prescribing physician’s instructions regarding timing and any required loading dose.

The most serious adverse events include severe liver injury, bone marrow suppression (which can lead to anemia, leukopenia, or thrombocytopenia), and interstitial lung disease. Patients should report signs such as jaundice, unusual bruising or bleeding, persistent cough, or shortness of breath promptly to their healthcare provider.

Leflunomide is contraindicated in pregnant women, women planning pregnancy, and nursing mothers. It should also be avoided in patients with pre‑existing severe liver disease, uncontrolled infections, or known hypersensitivity to the drug. Caution is advised for individuals with significant immunosuppression or pulmonary disorders.